Fat-Reduction Injectables

Fat-reduction injectable is a practical category, not a single drug class. Products marketed as “fat dissolvers” can include approved deoxycholic acid medicines, phosphatidylcholine (PPC) and deoxycholate mixtures, products presented as cosmetics or devices, and injectable products without authorization in the market where they are sold.

The finished formulation, intended use, legal classification, source, and jurisdiction matter more than the marketing term.

Product map

Product or term	Declared formulation	First regulatory question	Reference role
Kybella / Belkyra	Deoxycholic acid 10 mg/mL	Which regional brand and label apply?	Regulator-documented prescription-drug family
V-OLET	Deoxycholic acid 20 mg/2 mL	What does the current Korean or local label authorize?	Korean-developed prescription product
Rongzhi	Deoxycholic acid injection, 20 mg/2 mL	What do the NMPA record and Chinese label establish?	Chinese approval context
Aqualyx	Manufacturer-described deoxycholate-family compound	What is the current product classification and certificate?	European-origin product with changing identity claims
Lipo Lab	Presentation-dependent; PPC Solution is marketed as PPC + sodium deoxycholate	Is the exact presentation authorized for injection locally?	Online-market product family
Kabelline	Marketed as a deoxycholic-acid solution	Who manufactures it, and where is it authorized?	Online-market product with incomplete role documentation
Dr. Lipo+	Variant-dependent PPC, sodium deoxycholate, carnitine, and other declared ingredients	Which variant is being discussed, and what authorization supports injection?	Multi-presentation marketed product family
Lemon Bottle	Officially described as an external-use cosmetic; injection-labelled products have prompted warnings	Is the item an authentic external-use product or a product offered for injection?	Product-identity and market-surveillance case
Lipodissolve	Variable PPC/deoxycholate mixtures	What exactly was compounded or supplied?	Procedure and formulation term, not one verified brand

The US Food and Drug Administration states that Kybella is the only fat-dissolving injectable drug it has approved, and only for improvement of moderate-to-severe submental fullness in adults. The same FDA communication names Aqualyx, Lipodissolve, Lipo Lab, and Kabelline among products marketed online without FDA approval (FDA safety communication 🔗). This is a US regulatory statement, not a universal verdict on every other jurisdiction.

Read the identity before the ingredient

Active substance and salt form

Deoxycholic acid, sodium deoxycholate, and mixed PPC/deoxycholate formulations should not be collapsed into one interchangeable ingredient label. Product concentration, excipients, pH, presentation, and manufacturing controls remain product-specific.

Intended anatomical area

An authorization for adult submental fat does not establish safe or effective use in the abdomen, arms, thighs, back, or other areas. Broader body-contouring claims require their own product- and jurisdiction-specific support.

Product classification

“Cosmetic,” “medical device,” and “medicine” are legal classifications, not marketing synonyms. An injectable presentation may be treated differently by different authorities, and a historical CE-mark claim should not be assumed to describe current MDR status.

Company role

The brand promoter, product developer, approval holder, physical manufacturer, exporter, and local distributor may be different entities. This index records only the narrowest relationship supported by the cited source.

Focused reading paths

Start with	What it clarifies
Terminology and mechanisms	Why “fat dissolver,” injection lipolysis, DCA, deoxycholate, PPC, and Lipodissolve are not equivalent terms
Product and regulatory classification	How to separate an approved medicine, marketed solution, cosmetic, device claim, and unapproved drug
Regional regulation	Why approval must include a product, jurisdiction, indication, and date
DCA drugs vs PPC/deoxycholate mixtures	Which comparisons are supported and which are not
Safety and treatment boundaries	How formulation, anatomy, source, and technique affect risk interpretation

What this category excludes

This reference area does not include systemic weight-management medicines, oral supplements, topical slimming cosmetics, energy-based body-contouring devices, or liposuction. It focuses on products supplied, promoted, or encountered as localized injectable fat-reduction treatments.

Professional and product-specific scope

This index does not provide a universal injection grid, dose, depth, interval, or body-area protocol. Use depends on the exact authorized product, current local labeling, anatomy, training, clinical judgment, sterile practice, and readiness to recognize and manage complications.